OBJECTIVE: To determine if a regional quality improvement effort can increase beta-blocker utilization prior to vascular surgery and decrease the incidence of postoperative myocardial infarction (POMI). METHODS: A quality improvement effort to increase perioperative beta blocker utilization was implemented in 2003 at centers participating in the Vascular Study Group of New England (VSGNE). A 90% target was set and feedback given at biannual meetings. Beta blocker utilization (<1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008. Predictors of POMI were determined using multivariate logistic regression. Rates of beta blocker administration and POMI were analyzed over time, and across strata of patient risk based on a multivariate model. RESULTS: Perioperative beta blocker treatment increased from 68% of patients in the first 3 months of 2005 to 88% by the last 3 months of 2008 (P < .001). In 2003, 44% of patients not on chronic beta blockers were treated with preoperative beta blockers; by 2008, 78% of patients not on chronic beta blockers were started perioperatively on these medications (P < .001). Beta blocker utilization increased across all centers and surgeons participating during the study period, and increased in patients of low, medium, and high cardiac risk. However, the rate of POMI did not change over time (5.2% in 2003, 5.5% in 2008; P = .876), although a trend towards lower POMI rate was seen in patients on preoperative beta blockers (4.4% in 2003-2005, 2.6% in 2006-2008; P = .43). In multivariable modeling we found that age >70 (odds ratio [OR], 2.1), positive stress test (OR, 2.2), congestive heart failure (CHF; OR, 1.7), chronic beta blocker administration (OR, 1.7), resting heart rate <70 (OR, 1.8), and diabetes (OR, 1.6) were associated with POMI. Resting heart rate was similar for patients on chronic (67), preoperative (70), and no beta blockers (70; P = .521). CONCLUSIONS: Our regional quality improvement effort successfully increased perioperative beta blocker utilization. However, this was not associated with reduced rates of POMI or resting heart rate. While this demonstrates the effectiveness of regional quality improvement efforts in changing practice patterns, further work is necessary to more precisely identify those patients who will benefit from beta blockade at the time of vascular surgery.
OBJECTIVE: To determine if a regional quality improvement effort can increase beta-blocker utilization prior to vascular surgery and decrease the incidence of postoperative myocardial infarction (POMI). METHODS: A quality improvement effort to increase perioperative beta blocker utilization was implemented in 2003 at centers participating in the Vascular Study Group of New England (VSGNE). A 90% target was set and feedback given at biannual meetings. Beta blocker utilization (<1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008. Predictors of POMI were determined using multivariate logistic regression. Rates of beta blocker administration and POMI were analyzed over time, and across strata of patient risk based on a multivariate model. RESULTS: Perioperative beta blocker treatment increased from 68% of patients in the first 3 months of 2005 to 88% by the last 3 months of 2008 (P < .001). In 2003, 44% of patients not on chronic beta blockers were treated with preoperative beta blockers; by 2008, 78% of patients not on chronic beta blockers were started perioperatively on these medications (P < .001). Beta blocker utilization increased across all centers and surgeons participating during the study period, and increased in patients of low, medium, and high cardiac risk. However, the rate of POMI did not change over time (5.2% in 2003, 5.5% in 2008; P = .876), although a trend towards lower POMI rate was seen in patients on preoperative beta blockers (4.4% in 2003-2005, 2.6% in 2006-2008; P = .43). In multivariable modeling we found that age >70 (odds ratio [OR], 2.1), positive stress test (OR, 2.2), congestive heart failure (CHF; OR, 1.7), chronic beta blocker administration (OR, 1.7), resting heart rate <70 (OR, 1.8), and diabetes (OR, 1.6) were associated with POMI. Resting heart rate was similar for patients on chronic (67), preoperative (70), and no beta blockers (70; P = .521). CONCLUSIONS: Our regional quality improvement effort successfully increased perioperative beta blocker utilization. However, this was not associated with reduced rates of POMI or resting heart rate. While this demonstrates the effectiveness of regional quality improvement efforts in changing practice patterns, further work is necessary to more precisely identify those patients who will benefit from beta blockade at the time of vascular surgery.
Authors: Philip P Goodney; Brian W Nolan; Jens Eldrup-Jorgensen; Donald S Likosky; Jack L Cronenwett Journal: J Vasc Surg Date: 2010-10 Impact factor: 4.268
Authors: Don Poldermans; Jeroen J Bax; Olaf Schouten; Aleksandar N Neskovic; Bernard Paelinck; Guido Rocci; Laura van Dortmont; Anai E S Durazzo; Louis L M van de Ven; Marc R H M van Sambeek; Miklos D Kertai; Eric Boersma Journal: J Am Coll Cardiol Date: 2006-08-17 Impact factor: 24.094
Authors: Anne Benedicte Juul; Jørn Wetterslev; Christian Gluud; Allan Kofoed-Enevoldsen; Gorm Jensen; Torben Callesen; Peter Nørgaard; Kim Fruergaard; Morten Bestle; Rune Vedelsdal; André Miran; Jon Jacobsen; Jakob Roed; Maj-Britt Mortensen; Lise Jørgensen; Jørgen Jørgensen; Marie-Louise Rovsing; Pernille Lykke Petersen; Frank Pott; Merete Haas; Rikke Albret; Lise Lotte Nielsen; Gun Johansson; Pia Stjernholm; Yvonne Mølgaard; Nikolai Bang Foss; Jeanie Elkjaer; Bjørn Dehlie; Klavs Boysen; Dusanka Zaric; Anne Munksgaard; Jørn Bo Madsen; Bjarne Øberg; Boris Khanykin; Tine Blemmer; Stig Yndgaard; Grazyna Perko; Lars Peter Wang; Per Winkel; Jørgen Hilden; Per Jensen; Nader Salas Journal: BMJ Date: 2006-06-24
Authors: E Boersma; D Poldermans; J J Bax; E W Steyerberg; I R Thomson; J D Banga; L L van De Ven; H van Urk; J R Roelandt Journal: JAMA Date: 2001-04-11 Impact factor: 56.272
Authors: Meyer Kattan; Ellen F Crain; Suzanne Steinbach; Cynthia M Visness; Michelle Walter; James W Stout; Richard Evans; Ernestine Smartt; Rebecca S Gruchalla; Wayne J Morgan; George T O'Connor; Herman E Mitchell Journal: Pediatrics Date: 2006-06 Impact factor: 7.124
Authors: Huiling Zhang; Julia A Alexander; Josiah Luttrell; Gerald T O'Connor; Jennifer Daley; Martin Paris Journal: Am Heart J Date: 2005-05 Impact factor: 4.749
Authors: Andres Schanzer; Nathanael Hevelone; Christopher D Owens; Joshua A Beckman; Michael Belkin; Michael S Conte Journal: J Vasc Surg Date: 2008-04 Impact factor: 4.268
Authors: Reshma B Patel; Peter Beaulieu; Karen Homa; Philip P Goodney; Andrew C Stanley; Jack L Cronenwett; David H Stone; Daniel J Bertges Journal: J Vasc Surg Date: 2013-09-05 Impact factor: 4.268
Authors: Benjamin S Brooke; Randall R De Martino; Micah Girotti; Justin B Dimick; Philip P Goodney Journal: J Vasc Surg Date: 2012-06-26 Impact factor: 4.268
Authors: Randall R De Martino; Jens Eldrup-Jorgensen; Brian W Nolan; David H Stone; Julie Adams; Daniel J Bertges; Jack L Cronenwett; Philip P Goodney Journal: J Vasc Surg Date: 2014-01-16 Impact factor: 4.268